Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | USP4 | Q13107 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9502707 | 0.87 | HAO1 (0.36) | HDAC8CA1CA2CA12CA4 | |
| SCHEMBL3840593 | 0.78 | HDAC8 (0.43) | HDAC8CA1CA2CA12CA4 | |
| SCHEMBL5179689 | 0.78 | HDAC8 (0.43) | HDAC8CA1CA2CA12CA4 | |
| SCHEMBL28871 | 0.76 | HDAC8 (0.59) | HDAC8CA1CA2CA12CA4 | |
| SCHEMBL97582 | 0.76 | CA1 (0.52) | CA1CA2 | |
| SCHEMBL200142 | 0.74 | LOXL2 (0.58) | CA2CA12CA9CA14CYP2A6 | |
| SCHEMBL935811 | 0.74 | CYP2A6 (0.58) | HDAC8CA1CA2CA12CA4 | |
| SCHEMBL1253137 | 0.74 | TRPA1 (0.43) | HDAC8CA1CA2CA12CA4 | |
| SCHEMBL19437245 | 0.74 | HDAC8 (0.40) | HDAC8CA1CA2CA12CA4 | |
| SCHEMBL1802180 | 0.74 | CA1 (0.43) | CA1CA2FFAR1CYP2A6LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114878542-B | Be used for simultaneously detecting intracellular Cu of mitochondria+And Cu2+Surface-enhanced Raman spectrum probe of (2), preparation and application thereof | 华东师范大学 | 2025-02-11 | — | — | CN | claimed |
| CN-115548397-A | Preparation method and application of cross-linked anion exchange membrane | 宿迁时代储能科技有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-114878542-A | Method for simultaneously detecting Cu in mitochondria of cells + And Cu 2+ Surface enhanced Raman spectroscopy probe and preparation and application thereof | 华东师范大学 | 2022-08-09 | — | — | CN | claimed |
| EP-0857770-B1 | Coating compositions, hydrophilic films, and hydrophilic film-coated articles | SHINETSU CHEMICAL CO (JP) | 2004-09-22 | — | — | EP | claimed |
| EP-4293024-B1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4706774-A2 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-20260049072-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2026-02-19 | — | — | US | disclosed |
| US-20250340561-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12384794-B2 | Quinazoline compound for inducing degradation of G12D mutant KRAS protein | ASTELLAS PHARMA INC. (JP) | 2025-08-12 | — | — | US | disclosed |
| US-20250206751-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2025-06-26 | — | — | US | disclosed |
| EP-4568674-A1 | COMBINATION OF ANTICANCER AGENTS COMPRISING A BIFUNCTIONAL COMPOUND WITH G12D MUTANT KRAS INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2025-06-18 | — | — | EP | disclosed |
| EP-4568675-A1 | COMBINATION OF ANTICANCER AGENTS COMPRISING A BIFUNCTIONAL COMPOUND WITH G12D MUTANT KRAS INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20120052411-A9 | AROMATIC HYDROCARBON BASED PROTON EXCHANGE MEMBRANE AND DIRECT METHANOL FUEL CELL USING SAME | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2012-03-01 | — | — | US | disclosed |
| CN-101057357-B | Aromatic hydrocarbon based proton exchange membrane and direct methanol fuel cell using same | TOYO BOSEKI | 2011-06-22 | — | — | CN | disclosed |
| US-20090075147-A1 | Sulfonic acid group-containing polymer, method for producing the same, resin composition containing such sulfonic acid group-containing polymer, polymer electrolyte membrane, polymer electrolyte membrane/electrode assembly, and fuel cell | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2009-03-19 | — | — | US | disclosed |
| CN-101218281-A | Sulfonic acid group-containing polymer, method for producing same, resin composition containing such sulfonic acid group-containing polymer, polymer electrolyte membrane, polymer electrolyte membrane/ | TOYO BOSEKI (JP) | 2008-07-09 | — | — | CN | disclosed |
| EP-1889863-A1 | SULFONIC ACID GROUP-CONTAINING POLYMER, METHOD FOR PRODUCING SAME, RESIN COMPOSITION CONTAINING SUCH SULFONIC ACID GROUP-CONTAINING POLYMER, POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE/ELECTRODE ASSEMBLY, AND FUEL CELL | Toyo Boseki Kabushiki Kasisha (JP) | 2008-02-20 | — | — | EP | disclosed |
| CN-101057357-A | Aromatic hydrocarbon based proton exchange membrane and direct methanol fuel cell using same | TOYO BOSEKI (JP) | 2007-10-17 | — | — | CN | disclosed |
| US-20070207361-A1 | AROMATIC HYDROCARBON BASED PROTON EXCHANGE MEMBRANE AND DIRECT METHANOL FUEL CELL USING SAME | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1826846-A1 | AROMATIC HYDROCARBON-BASE PROTON EXCHANGE MEMBRANE AND DIRECT METHANOL FUEL CELL USING SAME | Toyo Boseki Kabushiki Kasisha (JP) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384794-B2 | Quinazoline compound for inducing degradation of G12D mutant KRAS protein | KRAS, NRAS, HRAS | HDAC8 2527/4885CA1 2560/4885CA2 971/4885 |
| US-20250206751-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | HDAC8 2315/4885CA1 1690/4885CA2 1409/4885 |
| US-20250340561-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | HDAC8 2527/4885CA1 2560/4885CA2 971/4885 |
| US-20260049072-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | HDAC8 2824/4885CA1 2146/4885CA2 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.